TickerFacts.

Cuprina Holdings (Cayman) Ltd (CUPR): R&D Expense

Annual figures by period end, from SEC filings.

226.9K SGD
Year ended 2025-12-31
-8.2%
3-year compound annual growth
292.9K SGD2022-12-31: 292.9K SGD2023-12-31: 167.7K SGD2024-12-31: 241.4K SGD2025-12-31: 226.9K SGD226.9K SGD
2022-12-31 R&D Expense (SGD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31226.9K SGD-6.0%2026-04-27, From 2025-01-01
2024-12-31241.4K SGD+43.9%2026-04-27, From 2024-01-01
2023-12-31167.7K SGD-42.7%2026-04-27, From 2023-01-01
2022-12-31292.9K SGDn/a2025-05-14, From 2022-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Orthopedic, Prosthetic & Surgical Appliances & Supplies), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
Cuprina Holdings (Cayman) Ltd (CUPR)2025-12-31226.9K SGD-6.0%
Phaos Technology Holdings (Cayman) Ltd (POAS)2025-04-30139.7K SGD+54.3%

Compare CUPR, POAS side by side · Screen every company in Orthopedic, Prosthetic & Surgical Appliances & Supplies ↗